Treatment of a severe vascular disease using a bespoke CRISPR-Cas9 base editor in mice.

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Nature Biomedical Engineering

• Publication date

  2025-09-11

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41551-025-01499-1PMID 40935887PMCID PMC12515372
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Population-scale cellular GUIDE-seq-2 and biochemical CHANGE-seq-R profiles reveal human genetic variation frequently affects Cas9 off-target activity

  2025cited by this paper
• Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease.

  2025cited by this paper
• Custom CRISPR–Cas9 PAM variants via scalable engineering and machine learning

  2025cited by this paper
• Treatment of a severe vascular disease using a bespoke CRISPR-Cas9 base editor in mice.

  2025cited by this paper
• Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model

  2024cited by this paper
• Assessing and engineering the IscB–ωRNA system for programmed genome editing

  2024cited by this paper
• Targeted nonviral delivery of genome editors in vivo

  2024cited by this paper
• CHANGE-seq-BE enables simultaneously sensitive and unbiased in vitro profiling of base editor genome-wide activity

  2024cited by this paper
• Gene Therapy in Cardiovascular Disease: Recent Advances and Future Directions in Science: A Science Advisory From the American Heart Association

  2024cited by this paper
• High-fidelity PAMless base editing of hematopoietic stem cells to treat chronic granulomatous disease

  2024cited by this paper
• Engineered IscB–ωRNA system with expanded target range for base editing

  2024cited by this paper
• An engineered hypercompact CRISPR-Cas12f system with boosted gene-editing activity

  2023cited by this paper
• Strategies for non-viral vectors targeting organs beyond the liver

  2023cited by this paper
• Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy

  2023cited by this paper
• PAM-flexible genome editing with an engineered chimeric Cas9

  2023cited by this paper
• Monogenic Causes of Cerebrovascular Disease in Childhood: A Case Series.

  2023cited by this paper
• An Engineered Adeno-Associated Virus Capsid Mediates Efficient Transduction of Pericytes and Smooth Muscle Cells of the Brain Vasculature

  2023cited by this paper
• Unraveling the mechanisms of PAMless DNA interrogation by SpRY-Cas9

  2023cited by this paper
• Deep learning models to predict the editing efficiencies and outcomes of diverse base editors

  2023cited by this paper
• In the business of base editors: Evolution from bench to bedside

  2023cited by this paper
• Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice

  2023cited by this paper
• Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

  2023cited by this paper
• Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease

  2023cited by this paper
• Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors

  2022cited by this paper
• Engineered Cas12i2 is a versatile high-efficiency platform for therapeutic genome editing

  2022cited by this paper
• The Genetic Basis of Strokes in Pediatric Populations and Insight into New Therapeutic Options

  2022cited by this paper
• An engineered xCas12i with high activity, high specificity, and broad PAM range

  2022cited by this paper
• Adenine Base Editing In Vivo with a Single Adeno-Associated Virus Vector

  2022cited by this paper
• Synergistic engineering of CRISPR-Cas nucleases enables robust mammalian genome editing

  2022cited by this paper
• Adenine base editor engineering reduces editing of bystander cytosines

  2021cited by this paper
• Scalable characterization of the PAM requirements of CRISPR–Cas enzymes using HT-PAMDA

  2021cited by this paper
• Precision genome editing using cytosine and adenine base editors in mammalian cells

  2021cited by this paper
• Defining genome-wide CRISPR–Cas genome-editing nuclease activity with GUIDE-seq

  2021cited by this paper
• Making the cut with PAMless CRISPR-Cas enzymes.

  2021cited by this paper
• MCOLN1 gene therapy corrects neurologic dysfunction in the mouse model of mucolipidosis IV.

  2021cited by this paper
• Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors

  2020cited by this paper
• Continuous evolution of SpCas9 variants compatible with non-G PAMs

  2020cited by this paper
• Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity

  2020cited by this paper
• Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants

  2020cited by this paper
• Directed evolution of adenine base editors with increased activity and therapeutic application

  2020cited by this paper
• Determinants of Base Editing Outcomes from Target Library Analysis and Machine Learning.

  2020cited by this paper
• CHANGE-seq reveals genetic and epigenetic effects on CRISPR-Cas9 genome-wide activity

  2020cited by this paper
• DNA capture by a CRISPR-Cas9–guided adenine base editor

  2020cited by this paper
• Targeted re-sequencing in pediatric and perinatal stroke.

  2020cited by this paper
• Base editing: advances and therapeutic opportunities

  2020cited by this paper
• Cerebrovascular Disease Progression in Patients With ACTA2 Arg179 Pathogenic Variants

  2020cited by this paper
• In Vivo Base Editing Rescues Hutchinson-Gilford Progeria Syndrome in Mice

  2020cited by this paper
• Adenine base editors catalyze cytosine conversions in human cells

  2019cited by this paper
• Genome-wide target specificity of CRISPR RNA-guided adenine base editors

  2019cited by this paper
• CRISPResso2 provides accurate and rapid genome editing sequence analysis

  2019cited by this paper
• Selection of an Efficient AAV Vector for Robust CNS Transgene Expression

  2019cited by this paper
• HDAC9 complex inhibition improves smooth muscle-dependent stenotic vascular disease.

  2019cited by this paper
• Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses

  2019cited by this paper
• HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype

  2019cited by this paper
• Search-and-replace genome editing without double-strand breaks or donor DNA

  2019cited by this paper
• Base editing: precision chemistry on the genome and transcriptome of living cells

  2018cited by this paper
• An HDAC9-MALAT1-BRG1 complex mediates smooth muscle dysfunction in thoracic aortic aneurysm

  2018cited by this paper
• Engineered CRISPR-Cas9 nuclease with expanded targeting space

  2018cited by this paper
• Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction

  2018cited by this paper
• Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing

  2018cited by this paper
• Minimal PAM specificity of a highly similar SpCas9 ortholog

  2018cited by this paper
• A stroke gene panel for whole-exome sequencing

  2018cited by this paper
• Clinical History and Management Recommendations of the Smooth Muscle Dysfunction Syndrome Due to ACTA2 Arginine 179 Alterations

  2018cited by this paper
• A communal catalogue reveals Earth’s multiscale microbial diversity

  2017cited by this paper
• Deep mutational scanning of S. pyogenes Cas9 reveals important functional domains

  2017cited by this paper
• Vascular disease-causing mutation, smooth muscle α-actin R258C, dominantly suppresses functions of α-actin in human patient fibroblasts

  2017cited by this paper
• Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems

  2016cited by this paper
• Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage

  2016cited by this paper
• Structural Plasticity of PAM Recognition by Engineered Variants of the RNA-Guided Endonuclease Cas9.

  2016cited by this paper
• Engineered CRISPR-Cas9 nucleases with altered PAM specificities

  2015cited by this paper
• High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets

  2015cited by this paper
• Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition

  2015cited by this paper
• In vivo genome editing using Staphylococcus aureus Cas9

  2015cited by this paper
• Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases

  2014cited by this paper
• GUIDE-Seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases

  2014cited by this paper
• R179H mutation in ACTA2 expanding the phenotype to include prune‐belly sequence and skin manifestations

  2012cited by this paper
• Cost-effective, high-throughput DNA sequencing libraries for multiplexed target capture

  2012cited by this paper
• A novel distinctive cerebrovascular phenotype is associated with heterozygous Arg179 ACTA2 mutations.

  2012cited by this paper
• De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunction

  2010cited by this paper
• Enzymatic assembly of DNA molecules up to several hundred kilobases

  2009cited by this paper
• The naturally split Npu DnaE intein exhibits an extraordinarily high rate in the protein trans‐splicing reaction

  2009cited by this paper
• Smooth muscle expression of Cre recombinase and eGFP in transgenic mice.

  2002cited by this paper

• Smooth Muscle Dysfunction Drives Cerebrovascular Reserve Failure and End-Organ Brain Injury

  2026cites this paper
• Advancing gene and base editing for cardiovascular disease: overcoming barriers in delivery, precision and safety.

  2026cites this paper
• Advances in Engineered Virus-Like Particles for Genome Editing and Therapy.

  2026cites this paper
• Structural and functional gastrointestinal abnormalities in ACTA2 R179H mice modeling multisystemic smooth muscle dysfunction syndrome.

  2026cites this paper
• Diagnosis and management of heritable thoracic aortic diseases

  2026cites this paper
• Expanding the CRISPR/Cas toolkit: applications in proteomics and theranostics

  2025cites this paper
• Treatment of a severe vascular disease using a bespoke CRISPR-Cas9 base editor in mice.

  2025cites this paper